Abstract
Background:This study measured serum concentrations of vascular risk factors, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in a representative sample of older community-dwelling adults and determined their associations with objective and subjective memory impairment. Methods: Data on clinical, lifestyle, and demographic characteristics, serum ADMA, SDMA, and L-arginine (measured using LC-MS/MS) were collected from a population-based sample of older Australian adults from the Hunter Community Study. Objective memory was measured with the Audio Recorded Cognitive Screen (ARCS) neuropsychological battery and subjective memory impairment was measured using the Memory Complaint Questionnaire (MAC-Q). Results: Multivariate analysis revealed that SDMA and diabetes were significantly associated with objective memory impairment (Adjusted Odd ratio (AOR) = 3.90; 95% CI. 1.21 – 12.52 for fourth quartile (Q4) of SDMA. ADMA, SDMA, education, number of general practitioner visits and atrial fibrillation were all significantly associated with subjective memory impairment. (AOR = 1.82; 95% CI. 1.04 – 3.18 for Q4 ADMA. Conclusions: Higher serum SDMA was associated with objective and subjective memory impairment while higher serum ADMA was associated with subjective memory impairment.
Keywords: ADMA, Alzheimer’s disease, memory impairment, methylarginines, nitric oxide, older adults, SDMA.
Current Alzheimer Research
Title:Memory Impairment is Associated with Serum Methylarginines in Older Adults
Volume: 11 Issue: 1
Author(s): Mark McEvoy, Peter Schofield, Wayne Smith, Kingsley Agho, Arduino A. Mangoni, Roy L. Soiza, Roseanne Peel and John Attia
Affiliation:
Keywords: ADMA, Alzheimer’s disease, memory impairment, methylarginines, nitric oxide, older adults, SDMA.
Abstract: Background:This study measured serum concentrations of vascular risk factors, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) in a representative sample of older community-dwelling adults and determined their associations with objective and subjective memory impairment. Methods: Data on clinical, lifestyle, and demographic characteristics, serum ADMA, SDMA, and L-arginine (measured using LC-MS/MS) were collected from a population-based sample of older Australian adults from the Hunter Community Study. Objective memory was measured with the Audio Recorded Cognitive Screen (ARCS) neuropsychological battery and subjective memory impairment was measured using the Memory Complaint Questionnaire (MAC-Q). Results: Multivariate analysis revealed that SDMA and diabetes were significantly associated with objective memory impairment (Adjusted Odd ratio (AOR) = 3.90; 95% CI. 1.21 – 12.52 for fourth quartile (Q4) of SDMA. ADMA, SDMA, education, number of general practitioner visits and atrial fibrillation were all significantly associated with subjective memory impairment. (AOR = 1.82; 95% CI. 1.04 – 3.18 for Q4 ADMA. Conclusions: Higher serum SDMA was associated with objective and subjective memory impairment while higher serum ADMA was associated with subjective memory impairment.
Export Options
About this article
Cite this article as:
McEvoy Mark, Schofield Peter, Smith Wayne, Agho Kingsley, Mangoni A. Arduino, Soiza L. Roy, Peel Roseanne and Attia John, Memory Impairment is Associated with Serum Methylarginines in Older Adults, Current Alzheimer Research 2014; 11 (1) . https://dx.doi.org/10.2174/15672050113106660178
DOI https://dx.doi.org/10.2174/15672050113106660178 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on the Evidence of Statin Treatment to Reduce Plaque Vulnerability
Drug Metabolism Letters The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Nutraceuticals: Beyond the Diet Before the Drugs
Current Bioactive Compounds Myocardial Contrast Echocardiography: Role in Clinical Cardiology
Current Vascular Pharmacology Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms
Current Vascular Pharmacology Interventions to Prevent Long-Term Consequences of Bronchiolitis
Current Respiratory Medicine Reviews New Biotechnological Methods to Reduce Oxidative Stress in the Cardiovascular System: Focusing on the Bach1/Heme Oxygenase-1 Pathway
Current Pharmaceutical Biotechnology Radionuclide Imaging in Patients with Ischemic Heart Failure
Current Medical Imaging Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism The Pharmacology of LXR
Mini-Reviews in Medicinal Chemistry Melatonin in Cardiac Ischemia/Reperfusion-Induced Mitochondrial Adaptive Changes
Cardiovascular & Hematological Disorders-Drug Targets Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
Current Pharmaceutical Design Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Zinc and Cell Signaling During Inflammation: Implications in Atherosclerosis
Current Nutrition & Food Science Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Genetic and Non-genetic Determinants of Cardiovascular Disease in South Asians
Current Diabetes Reviews Weka Machine Learning for Predicting the Phospholipidosis Inducing Potential
Current Topics in Medicinal Chemistry The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design